A tumor microenvironment-specific gene expression signature predicts chemotherapy resistance in colorectal cancer patients
Open Access
- 12 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in npj Precision Oncology
- Vol. 5 (1), 1-14
- https://doi.org/10.1038/s41698-021-00142-x
Abstract
Studies have shown that tumor microenvironment (TME) might affect drug sensitivity and the classification of colorectal cancer (CRC). Using TME-specific gene signature to identify CRC subtypes with distinctive clinical relevance has not yet been tested. A total of 18 “bulk” RNA-seq datasets (total n = 2269) and four single-cell RNA-seq datasets were included in this study. We constructed a “Signature associated with FOLFIRI resistant and Microenvironment” (SFM) that could discriminate both TME and drug sensitivity. Further, SFM subtypes were identified using K-means clustering and verified in three independent cohorts. Nearest template prediction algorithm was used to predict drug response. TME estimation was performed by CIBERSORT and microenvironment cell populations-counter (MCP-counter) methods. We identified six SFM subtypes based on SFM signature that discriminated both TME and drug sensitivity. The SFM subtypes were associated with distinct clinicopathological, molecular and phenotypic characteristics, specific enrichments of gene signatures, signaling pathways, prognosis, gut microbiome patterns, and tumor lymphocytes infiltration. Among them, SFM-C and -F were immune suppressive. SFM-F had higher stromal fraction with epithelial-to-mesenchymal transition phenotype, while SFM-C was characterized as microsatellite instability phenotype which was responsive to immunotherapy. SFM-D, -E, and -F were sensitive to FOLFIRI and FOLFOX, while SFM-A, -B, and -C were responsive to EGFR inhibitors. Finally, SFM subtypes had strong prognostic value in which SFM-E and -F had worse survival than other subtypes. SFM subtypes enable the stratification of CRC with potential chemotherapy response thereby providing more precise therapeutic options for these patients.Keywords
This publication has 95 references indexed in Scilit:
- Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic ValuePLoS Medicine, 2013
- A colorectal cancer classification system that associates cellular phenotype and responses to therapyNature Medicine, 2013
- Dependency of Colorectal Cancer on a TGF-β-Driven Program in Stromal Cells for Metastasis InitiationCancer Cell, 2012
- Comprehensive molecular characterization of human colon and rectal cancerNature, 2012
- Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon CancerJAMA, 2012
- Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysisBritish Journal of Cancer, 2011
- PathSeq: software to identify or discover microbes by deep sequencing of human tissueNature Biotechnology, 2011
- Experimentally Derived Metastasis Gene Expression Profile Predicts Recurrence and Death in Patients With Colon CancerGastroenterology, 2010
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1Nature, 2009
- The tumor microenvironment and its role in promoting tumor growthOncogene, 2008